- Happy New Year\! As of January 29, 2026, fifteen Level 1, eight Level 2, one Level 3 and one Level 4 treatments for unique biomarker-selected indications were added to OncoKB. A table summarizing these changes can be found [here](https://www.oncokb.org/year-end-summary#2025). The “Precision Oncology: 2025 in Review” article can be found [here](https://aacrjournals.org/cancerdiscovery/article-abstract/15/12/2414/767704/Precision-Oncology-2025-in-ReviewPrecision?).

**Updated Therapeutic Implications**

- Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)

| Level | Gene  | Mutation      | Cancer Type   | Level-Associated Drug(s) in OncoKB™                                                                                                                                | Drug(s) Added to OncoKB™                        | Evidence                                                                                                                                                                                                                                                                       |
| :---- | :---- | :------------ | :------------ | :----------------------------------------------------------------------------------------------------------------------------------------------------------------- | :---------------------------------------------- | :----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| 1     | ERBB2 | Amplification | Breast Cancer | Trastuzumab, Trastuzumab Deruxtecan, Ado-Trastuzumab Emtansine, Margetuximab, Neratinib, Lapatinib, Trastuzumab \+ Pertuzumab, Trastuzumab \+ Tucatinib (Level 1\) | Trastuzumab Deruxtecan \+ Pertuzumab (Level 1\) | [FDA approval of trastuzumab deruxtecan with pertuzumab](https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive); PMID: [41160818](https://pubmed.ncbi.nlm.nih.gov/41160818/) |

- Addition of 9 new genes:
  - AAMP
  - APCDD1
  - ASXL3
  - BACH1
  - ESCO1
  - FCGR2B
  - H4C9
  - HIP1
  - PAFAH1B2
